A Message From Brownstone Research

Jeff Brown is the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years in advance. He's now predicting Elon Musk is about to open a new wealth window by October 30. Click here to see the details or read more below because the last three times this window opened, those who acted had a chance to walk away with generational wealth.

Dear Reader,

Have you seen this Elon Musk new project?

He called it "the most epic AI project in history…"

Because it could help him secure 50 times MORE computing power than the entire rest of the world.

This is all part of Elon Musk's $320 trillion masterplan…

A blueprint to completely dominate the entire AI industry.

And I'm pretty sure this is keeping executives at Amazon, Microsoft, and Google up at night.

But what does this mean for you?

Well, Elon is predicting this could be 180 times bigger than the SpaceX IPO.

That IPO minted 4,400 millionaires overnight.

If this is 180 times bigger…

Just imagine how many more Americans will become millionaires.

Will you be one of them?

Or will you just watch others get rich from the sidelines?

Click here to see the details and decide for yourself.

We have so much to look forward to,

Jeff Brown
Founder & CEO, Brownstone Research

A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?

Authored by Jeffrey Neal Johnson. Posted: 10/13/2026.

Micron Technology, Inc. (NASDAQ: MU) recently saw its share price decline amid concerns about advances in Chinese memory technology. Despite the recent pressure, Micron Technology retains a year-to-date gain of more than 220%. The divergence between the company's underlying financial performance and the market's immediate reaction creates a compelling setup for investors evaluating the longevity of the memory cycle.

A mixture of international headlines triggered the sell-off, prompting concerns about future pricing power and potential capacity gluts. Assessing whether these threats carry long-term weight or are merely a sentiment-driven blip requires looking past the noise and examining the underlying supply-and-demand dynamics of the semiconductor market.

Market Contagion: Separating Headline Noise From Data

Markets do not like uncertainty, and memory chip stocks are notoriously sensitive to any hint of future oversupply. The catalyst for the recent contraction largely stems from China-based ChangXin Memory Technologies (CXMT). The company announced developmental progress on a denser 4F square DRAM architecture, explicitly targeting the high-end server memory segment. Combined with a localized union strike authorization at Micron's Taoyuan manufacturing operations in Taiwan, the headlines created a difficult environment for institutional positioning.

Contrasting these fears with actual earnings performance reveals a possible disconnect. Micron Technology reported fiscal fourth-quarter revenue of $54.23 billion, up about 379% year over year. Adjusted earnings topped $33 per share. These results reflect a business operating at exceptionally strong levels of profitability. The market reaction appears to reflect anxieties about events that may not materialize for years. The trailing price-to-earnings ratio sits around 12.60, while the discounted forward multiple is approximately 5.37, indicating skepticism about the durability of peak-cycle earnings.

Lab Leak: Projecting China's 2026 Memory Goals

Understanding the details of the ChangXin Memory Technologies announcement helps separate genuine competitive risks from geopolitical noise. The company claims to have made progress in developing a 4F square DRAM design, which theoretically increases storage density. Its goal is to launch a server memory product based on this architecture by the end of 2026.

The timeline is the critical variable. The 4F square architecture has not yet demonstrated commercial-scale production, despite CXMT's plans to introduce a product before year-end. The memory market has high barriers to entry, including yield rates, packaging reliability and enterprise-grade validation. A state-backed competitor could eventually pressure long-term pricing floors across the DRAM market. However, a production target set for late 2026 does not necessarily alter the current supply-and-demand imbalance in the high-end server memory market. Projecting theoretical capacity additions onto current valuations can contribute to mispricing, particularly in a sector driven by immediate artificial intelligence (AI) hardware requirements.

Collateral Damage: Contagion in the Memory Oligopoly

The market reaction suggests that the recent news contributed to broad industry selling rather than a reassessment of Micron alone. SK hynix Inc. (NASDAQ: SKHY) fell more than 4% during the same trading window. Equipment manufacturers also caught the downdraft, with several semiconductor equipment stocks declining.

When the entire supply chain sells off simultaneously, investors may be pricing in a sector-wide threat of future oversupply and potential margin compression. Memory markets are inherently cyclical, and Wall Street remains highly attentive to any signal that the current upcycle may be peaking. Adding to the sector-wide pressure, supply chain reports suggest that equipment providers could raise prices by roughly 10% for competitors such as Samsung (OTCMKTS: SSNLF) and SK hynix. While this is not directly aimed at all memory makers, it signals broader capital expenditure inflation that could squeeze margins across the manufacturing sector.

Friction Points: Insider Sales and Labor Disputes

Beyond potential future supply threats, a few immediate friction points warrant attention. A local union at Micron's Taoyuan, Taiwan, manufacturing hub officially authorized a strike over bonus structures. No strike date has been announced. While labor disputes are common in heavy manufacturing, Taiwan is a critical production center. Any prolonged work stoppage could create a localized risk to production output and customer delivery commitments.

Micron Technology also recently agreed to a $600 million settlement regarding a Netlist patent dispute. Under the agreement, Micron will pay $30 million per quarter over five years beginning in the fourth quarter of 2026, rather than making a single $600 million payment. This creates a cash headwind for future free cash flow models. Coupled with recent insider sales totaling roughly $90 million over the trailing 90 days, including shares sold by Chief Executive Officer Sanjay Mehrotra, it is understandable why some institutional players may have opted to secure profits after a historic run-up. While insider selling does not inherently signal fundamental weakness, it can exacerbate downward momentum during periods of elevated volatility.

Demand Visibility and Strategic Buybacks

Balancing the speculative risks against the fundamental data paints a different picture. Micron Technology has already secured customer commitments covering more than 75% of its fiscal 2027 output, with customers actively discussing 2028 allocations. A potential Chinese product arriving in late 2026 would enter a market where most capacity is already spoken for by major enterprise clients.

The profitability metrics are equally compelling. Micron's fiscal 2026 net margin reached approximately 63.8%, reflecting its exceptionally strong earnings performance. Because Wall Street is pricing in a cyclical peak, the stock trades at a compressed forward multiple of approximately 5.4. This presents an interesting valuation disconnect. Management appears to recognize this disparity and recently authorized an approximately $35 billion share repurchase program. A buyback of this scale signals internal confidence in sustained free cash flow generation and could provide a structural floor for Micron's stock price.

Investors monitoring the memory space may want to watch upcoming earnings reports for signs of stability in memory contract pricing and the trajectory of gross margins. If pricing leverage holds firm against the geopolitical noise, the current pullback could represent a structural mispricing rather than the beginning of a prolonged cyclical downturn.

A Message From Behind the Markets

Fellow Investor,

The biggest energy deadline in American history...

Just aimed its full firepower at ONE company.

See, on July 4th, the One Big Beautiful Bill Act killed the federal tax credits that powered alternative energy for years.

But here's what almost nobody knows:

When the White House killed credits for solar, wind, EVs, and every other renewable energy source in America…

They left one untouched.

Not only that - they reclassified it alongside oil and nuclear...

And gave it eight years of credits.

Because in June 2025, a drilling crew working near the Grand Canyon...

Unearthed a well of clean energy producing almost 8 times the output of the largest oil well in Saudi Arabia...

Capable of powering civilization for two million years.

Right here on American soil.

Everything changed that day.

Google signed a 15-year contract...

Bill Gates wrote a $100 million check.

And on July 4th, the government handed this energy source its biggest advantage ever.

One company owns the entire chain.

Time is running out to be an "early investor."

I recommend placing your trade at tomorrow's market open.

Go here now for the Grand Canyon breakthrough ticker >>

"The Buck Stops Here,"

Dylan Jovine, CEO and Founder
Behind the Markets

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock

Submitted by Nathan Reiff. Originally Published: 10/26/2026.

GLP-1 agonists may have attracted most of the attention when it comes to game-changing drugs in the last couple of years, but the oncology landscape is heating up as well. Investors may see a transformation for some long-standing firms in the space. Bristol-Myers Squibb (NYSE: BMY) recently announced that its investigational drug candidate iza-brentuximab (Iza-bren) demonstrated a reduction in the risk of progression or death in a breast cancer trial.

The Phase 3 trial data comes at a crucial time for the firm as it faces the ongoing threat of a major patent cliff for its popular blood cancer drug Revlimid. At its peak, the drug generated nearly $13 billion in annual sales, but that was in 2021, and generic competition has eroded those sales in the years since. Given that breast cancer is the largest oncology indication in the country, any drug that can meaningfully improve progression-free survival has the potential to become another multibillion-dollar product.

The Potential Implications of the Iza-bren Trial Data

The Iza-bren trial focused on patients with HER2-low and HER2-ultralow metastatic cancers, common types of breast cancer that account for up to two-thirds of all metastatic breast cancer cases. Despite their prevalence, these cancers are currently underserved by existing therapies.

The Phase 3 trial data showed a 59% reduction in the risk of disease progression or death compared with chemotherapy—a significant benefit. This is crucial for BMY, as it suggests that Iza-bren is not merely promising but has meaningful potential for large-scale commercialization.

Despite the positive clinical results, BMY shares fell about 2.4% on Oct. 23. Nonetheless, analysts remain divided on the stock, with more than half still calling BMY a Hold. The company had strong Q2 2026 results, including better-than-expected earnings and revenue, as well as an increase to its full-year guidance. However, the threat of delays to other critical trial results, along with additional pressures, has prompted analysts to expect slower revenue growth and a contraction in earnings per share (EPS) in the next quarterly report.

BMY stock trades at approximately 9.5 times forward earnings, a relatively modest valuation compared with the broader market. At the same time, the company continues to generate meaningful revenue despite pressure on Revlimid, thanks in part to other major offerings such as Opdivo and Eliquis. If Iza-bren receives FDA approval, the oncology market may support several billion dollars in additional annual sales for the drug, which would go a long way toward reaccelerating sales growth.

Impacts for the Broader Oncology Space

Though Bristol-Myers Squibb would likely be the biggest beneficiary of Iza-bren's approval, other companies in the oncology market may also be affected. Exelixis Inc. (NASDAQ: EXEL), a biopharma firm known for Cabometyx, a treatment for certain types of carcinomas and thyroid cancers, is one such company.

Cabometyx is the primary driver of Exelixis' revenue, with the broader cabozantinib franchise generating $573 million in U.S. net product revenue in Q2 2026, up about 10% year over year. Cabometyx accounted for approximately $571 million of that total. Although the company's revenue fell modestly short of analyst estimates, it posted a solid six-cent EPS beat.

What Exelixis needs, however, is renewed momentum. The company lowered its 2026 revenue and net product revenue guidance because of slower-than-expected adoption in some product areas. Meanwhile, it awaits an FDA decision on a leading colorectal cancer candidate.

Iza-bren's success bodes well for Exelixis for at least two reasons. First, as an antibody-drug conjugate, Iza-bren demonstrates that its particular mechanism can generate a notable clinical response. Exelixis has its own targeted breast cancer therapy that may operate through a similar mechanism.

Second, the approval and commercial launch of Iza-bren would likely draw interest from companies across the healthcare sector that have established oncology infrastructure, and Exelixis fits that profile. As a mid-sized oncology company with a demonstrated record of revenue success from its primary product and other products in the pipeline, it could become a potential acquisition target for larger firms.

To be sure, all of this is speculative and would hinge on Iza-bren's continued success and eventual commercialization. In the meantime, analysts are even more cautious about EXEL shares than about BMY, with just seven calling EXEL a Buy, 12 calling it a Hold and one calling it a Sell. This highlights the high-risk, high-reward proposition of many biopharma firms, including more established companies that have already demonstrated their ability to develop commercially successful drugs. It's a risk that investors must keep in mind.